

Amendments to the Specification:

Please replace the paragraph beginning at page 8, line 13 with the following amended paragraph:

To obtain an efficient dispersion of the glucocorticosteroid particles in the suspension, a surfactant may be used, optionally in combination with e.g., lecithin. The surfactants may also function as stabilizing agents in the formulations according to the present invention. Examples of suitable surfactants include non-ionic surfactants of the alkyl aryl polyether alcohol type, specifically ~~Tyloxapol~~<sup>TM</sup> tyloxapol – a polymer of 4-(1,1,3,3-tetramethylbutyl)phenol with ethylene oxide and formaldehyde. Further suitable surfactants include sorbitan derivatives, e.g. polyoxyethylene sorbitan fatty acid esters, preferably of the ~~Polyserbate~~ polysorbate or Tween<sup>TM</sup> groups, more preferably ~~Polyserbate~~ polysorbate 80 or polyoxyethylene 20 sorbitan monooleate (Tween<sup>TM</sup> 80). Suitable surfactants also include polyoxyethylene ethers, especially polyoxyethylene alkyl ethers, preferably pentaethyleneglycol mono n-dodecylether or C<sub>12</sub>E<sub>5</sub>. Further suitable surfactants include poloxamers, polyoxyethylene castor oil derivatives, polyvinylalcohol and block copolymers of polyethyleneoxides, polypropyleneoxides, polybutyleneoxides and polyethyleneglycols (PEGs) or mixtures of any of these. Further suitable surfactants include polyethylene glycol derivatives, especially polyethylene glycol 660 hydroxystearate or Solutol<sup>TM</sup> HS 15, povidone, polyvinylpyrrolidone (PVP) and polyethyleneglycols (PEGs).